AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03648931 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-depth Interview (IDI)
Description: No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women
Study NCT02173964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pinaverium bromide
Description: pinverin 50 mg per oral single dose versus simple water ingestion
Study NCT02173964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: same amount of water for pinverin administration
Study NCT01496118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Specified dose on specified days
Study NCT01496118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Specified dose on specified days
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to Sitagliptin 100mg
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to Sitagliptin 100mg
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI 10773 high dose tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets 100 mg once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily
Study NCT01177813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily
Study NCT02147860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) with USS Virginia
Description: DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
Study NCT02147860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
Study NCT01521949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acai Juice Product
Description: 2 ounces of Acai Juice Product twice daily.
Study NCT03413371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study NCT04086303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LSST test
Description: LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
Study NCT04086303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSST test
Description: LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
Study NCT02004652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
Study NCT02004652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin, 50mg, tablet.
Study NCT01650779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
Study NCT05665985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera
Description: Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
Study NCT05665985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moringa Oleifera
Description: Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
Study NCT06337851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous burr hole craniostomy
Description: Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MultiHance 0.1 mmol/kg
Description: MultiHance administered at 0.1 mmol/kg
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance 0.1 mmol/kg
Description: MultiHance administered at 0.1 mmol/kg
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg
Study NCT06337851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive burr hole craniostomy
Description: In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
Study NCT05611463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Docetaxel and Cisplatin
Description: Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
Study NCT03595215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation
Study NCT03903029 — intervention group
Intervention type: DRUG
Intervention: Low-dose (10mg) rosuvastatin
Description: Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
Study NCT03819946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal cooling device (Attune Medical, Chicago, IL)
Description: The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
Study NCT03819946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard esophageal temperature probe
Description: If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MultiHance 0.05 mmol/kg
Description: MultiHance administered at 0.05 mmol/kg
Study NCT02070380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance 0.05 mmol/kg
Description: MultiHance administered at 0.05 mmol/kg
Study NCT03023683 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: Influenza Virus Vaccine Live, Intranasal Spray
Study NCT02540902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibia (Aesculap AG)
Description: Implantation of an all polyethylene tibial component.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study NCT01253330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
Study NCT03385642 — intervention group
Intervention type: DEVICE
Intervention: ChondroMimetic
Description: ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
Study NCT01560559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy
Description: An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips.
Study NCT02544087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ixeris of sonchifolia Hance
Description: KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study NCT02544087 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Panax notoginseng saponins
Description: Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study NCT04590079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation
Description: Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
Study NCT02544087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
Description: KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study NCT01772693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS
Description: ExAblate Transcranial MR Guided Focused Ultrasound
Study NCT01772693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ExAblate Transcranial MRgFUS
Description: Sham ExAblate Transcranial MR Guided Focused Ultrasound
Study NCT03090542 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: clinoptilolite
Description: randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
Study NCT02719574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
Study NCT02719574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care
Study NCT03413371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study NCT02719574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: low-dose cytarabine will be administered per site's standard of care
Study NCT00253955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT00253955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Study NCT04410133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Study NCT00757107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taperloc Microplasty
Description: primary total hip arthroplasty
Study NCT00757107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc standard
Description: primary total hip arthroplasty
Study NCT03492411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Breastfeeding Co-parenting Resource
Description: The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
Study NCT01111409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFIX Device
Description: Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
Study NCT04020575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
Study NCT04020575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Description: huMNC2-CAR44 T cells or huMNC2-CAR22 CAR T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
Study NCT03690323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
Study NCT03413371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % ropivacaine with of 2% lidocaine
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study NCT03413371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 % Ropivacaine
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
Study NCT03413371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
Study NCT03252678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a book and videos about ACP
Description: A book and three videos about advanced care planning are provided for self-education
Study NCT03252678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a book and videos about pain control
Description: A book and three videos about pain control for cancer patients are provided for self-education
Study NCT04126525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: dual HER2 blockade in the neoadjuvant setting
Study NCT01326585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection
Description: 8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
Study NCT01326585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: 2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
Study NCT04583319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EasyCov POC
Description: Saliva samples will be collected according to the sampling protocol defined each for EASYCOV test. The EasyCoV test will be performed at the beginning of the study before obtaining the routine RT- PCR test results. The operators performing this test will be blinded from the routine RT-PCR results.
Study NCT03444688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Training
Description: Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
Study NCT03502707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF Protein 50 mcg
Description: RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
Study NCT02055911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
Study NCT01662050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Bendamustine, Cytarabine.
Description: 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
Study NCT02845154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bolus purge
Description: complete and uninterrupted purge
Study NCT02845154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent purge
Description: intermittent portal purge
Study NCT01175330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil emulsion (Omegaven)
Description: Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)